A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer

Journal of Chemotherapy

Volumn 10, Issue 4, 1998, Pages 326-330

  Pronzato, P ^a   Tognoni, A ^a   Pensa, F ^a   Vaira, F ^a   Vigani, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Advanced breast cancer; Breast cancer; Epidoxorubicin; Granulocyte colony stimulating factor; Vinorelbine

Indexed keywords

DEXAMETHASONE; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; HUMAN; LEUKOPENIA; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031826293     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.4.326     Document Type: Article

References (16)

1. Henderson IC, Garber JE, Bretmeyer JD, et al. Comprehensive management of disseminated breast cancer. Cancer 1990; 66: 1439-1448.
2. Hudis CA, Norton L. Adjuvant drug therapy for operable breast cancer. Sem Oncol 1996; 23: 475-493.
3. Hoogenstraten AB, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
4. Bonadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin (review). Ann Oncol 1993; 4: 359-369.
5. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127-142.
6. Fumoleau P, Deloziers T, Extra JM, et al. Vinorelbine in the treatment of breast cancer: the european experience. Semin Oncol 1995; 22 (2): 22-29.
7. Canobbio L, Boccardo F Pastorino G, et al. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16 (suppl 2): 33-36.
8. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase If study. J Clin Oncol 1994; 12: 2094-2101.
9. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first line and second line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-2730.
10. Spielmann M, Dorval T, Turpin F, et al. Phase II trial of Vinorelbine/Doxorubicin as first line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764-1770.
11. Pronzato P, Queirolo P, Landucci M, et al. Phase II study of vinorelbine and Ifosfamide in anthracycline resistent metastatic breast cancer. Breast Cancer Res Treat 1997; 42: 183-186.
12. 2) in the FEC regimen significantly increases response rates. An international randomized phase III study in metastatic breast cancer Ann Oncol 1997; 8: 155-162.
13. Pronzato P, Bertelli G, Vigani A, Vaira F. A feasibility study of accelerated polychemotherapy with cisplatin, epidoxorubicin and cyclophosphamide (PEC) in advanced ovarian cancer. Br J Cancer 1996; 73: 1425-1427.
14. Ardizzoni A, Venturini M, Crinò L, et al. High dose intensity chemotherapy, with accelerated cyclophosphamide, doxorubicin, etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer 1993; 29A: 687-692.
15. Pronzato P, Bertelli G, Bruna F, et al. Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer. Anticancer Res 1997; 17: 2325-2328.
16. Ardizzoni A, Venturini M, Sertoli MR, et al. Granulocyte-macrophage colony stimulating factor allows acceleration and dose intensity increase of CEF chemotherapy: a randomized study in patients with advanced breast cancer. Br J Cancer 1994; 69: 385-391.